# Women's Cancer Program

> **NIH NIH P30** · MAYO CLINIC ROCHESTER · 2020 · $100,686

## Abstract

WOMEN'S CANCER PROGRAM PROJECT SUMMARY
The Women's Cancer Program (WCP) is a highly interactive, multidisciplinary research program co-led by Drs.
Goetz, Degnim, and Bakkum-Gamez and composed of 61 basic and population scientists and clinical
investigators from 14 departments and centers at Mayo Clinic in Rochester, MN; Arizona; and Florida. Its
overarching goal is to advance the understanding of, and management strategies for, breast and gynecologic
cancers. The substantial intraprogrammatic interactions reflect multidisciplinary WCP teams that focus on 4
major Specific Aims: 1) Genomics: to determine both host and tumor genetic alterations; 2) Biology: to define
key mediators and pathways in the biology of women's cancers; 3) Advances in risk assessment: to define
subgroups of women at increased risk; and 4) New clinical strategies: to develop and test innovative clinical
strategies, especially based on discoveries from Specific Aims 1-3. The WCP's solid scientific base and
opportunities for interactions have resulted in the renewal of the Mayo Clinic Breast and Ovarian SPOREs and
new Stand Up to Cancer, DoD, and multiple R01 grants during the current project period. All of these grants
support investigator-initiated clinical trials at Mayo Clinic and within clinical trial networks, including the Alliance
for Clinical Trials, the Translational Breast Cancer Research Consortium, and the Stand Up to Cancer
collaboration, with broad participation by Program members. Total direct peer-reviewed grant funding within
the Program is $5.3M, with 56% from NCI. The Program has an additional $14.4M in direct, non-peer-reviewed
funding. Since 2013, Program members have contributed 978 publications to the literature; 49% represent
intraprogrammatic work, 29% reflect interprogrammatic collaborations, and 158 (16%) are in journals with an
impact factor ≥10. Some of this work has changed clinical practice, including reclassification of BRCA2 variants
of unknown significance; development and implementation of a new breast cancer risk model; co-development
of rucaparib, resulting in FDA approval and extension of PARP inhibitors beyond high-grade serous ovarian
cancers with germline BRCA1 or BRCA2 mutations; and the development of Clinical Pharmacogenetics
Implementation Consortium (CPIC) practice guidelines regarding the use of CYP2D6 genotype to guide
tamoxifen treatment. WCP members benefit from the use of numerous Shared Resources, especially
Biospecimens Accessioning and Processing, Pathology Research, Biostatistics, Survey Research, and
the MCCC Clinical Research Office. To catalyze new and maintain ongoing collaborations, the Program has
monthly scientific symposia and Breast and Gynecologic Cancer Disease Group meetings, weekly
multidisciplinary conferences for breast and gynecologic cancer researchers, quarterly combined breast and
gynecologic cancer conferences, and yearly multidisciplinary breast CME courses that rotate among the 3
Mayo sites. There is ...

## Key facts

- **NIH application ID:** 9938475
- **Project number:** 5P30CA015083-46
- **Recipient organization:** MAYO CLINIC ROCHESTER
- **Principal Investigator:** MATTHEW Philip GOETZ
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $100,686
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9938475

## Citation

> US National Institutes of Health, RePORTER application 9938475, Women's Cancer Program (5P30CA015083-46). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9938475. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*